Extrapolation of ACOSOG Z0011 trial results—A survey of breast cancer providers

2021 ◽  
Author(s):  
Anna Weiss ◽  
Victoria Cooley ◽  
Zahraa Al‐Hilli ◽  
Karla Ballman ◽  
Nancy Poorvu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Acosog Z0011 ◽  
Z0011 Trial

ASO Visual Abstract: The Attitudes of Brazilian Breast Surgeons on Axillary Management in Early Breast Cancer 10 Years After the ACOSOG Z0011 Trial First Publication

2021 ◽  
Author(s):  
Eduardo Camargo Millen ◽  
Francisco Pimentel Cavalcante ◽  
Felipe Zerwes ◽  
Guilherme Novita ◽  
Alessandra Borba Anton de Souza ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Acosog Z0011 ◽  
Z0011 Trial

AB059. 228. The impact of ACOSOG Z0011 trial on axillary management of breast cancer in the Galway University Hospitals

2018 ◽  
Vol 2 ◽  
pp. AB059-AB059
Author(s):  
Ellen O’Beirne ◽  
Peter McAnena ◽  
Ishwarya Balasubramanian ◽  
Aoife Lowery ◽  
Michael Kerin
Keyword(s):  
Breast Cancer ◽  
University Hospitals ◽  
Acosog Z0011 ◽  
Z0011 Trial ◽  
The Impact

scholarly journals Analyzing non-sentinel axillary metastases in patients with T3–T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy

2020 ◽  
Vol 184 (2) ◽  
pp. 627-636
Author(s):  
Fabian Riedel ◽  
Joerg Heil ◽  
Manuel Feisst ◽  
Mareike Moderow ◽  
Alexandra von Au ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Early Breast Cancer ◽  
Tumor Burden ◽  
Sentinel Lymph Nodes ◽  
Axillary Lymph ◽  
Axillary Metastases ◽  
Eligibility Criteria ◽  
Acosog Z0011 ◽  
Z0011 Trial

Abstract Purpose In the ACOSOG Z0011 trial, completing axillary lymph node dissection (cALND) did not benefit patients with T1–T2 cN0 early breast cancer and 1–2 positive sentinel lymph nodes (SLN) undergoing breast-conserving surgery (BCT). This paper reports cALND rates in the clinical routine for patients who had higher (T3–T4) tumor stages and/or underwent mastectomy but otherwise met the ACOSOG Z0011 eligibility criteria. Aim of this study is to determine cALND time trends and non-sentinel axillary metastases (NSAM) rates to estimate occult axillary tumor burden. Methods Data were included from patients treated in 179 German breast cancer centers between 2008 and 2015. Time-trend rates were analyzed for cALND of patients with T3–T4 tumors separated for BCT and mastectomy and regarding presence of axillary macrometastases or micrometastases. Results Data were available for 188,909 patients, of whom 19,009 were identified with 1–2 positive SLN. Those 19,009 patients were separated into 4 cohorts: (1) Patients with T1–T2 tumors receiving BCT (ACOSOG Z0011 eligible; n = 13,741), (2) T1–T2 with mastectomy (n = 4093), (3) T3–T4 with BCT (n = 269), (4) T3–T4 with mastectomy (n = 906). Among patients with T3–T4 tumors, cALND rates declined from 2008 to 2015: from 88.2 to 62.6% for patients receiving mastectomy and from 96.6 to 58.1% in patients receiving BCT. Overall rates for any NSAM after cALND for cohorts 1–4 were 33.4%, 42.3%, 46.9%, 58.8%, respectively. Conclusions The cALND rates have decreased substantially in routine care in patients with ‘extended’ ACOSOG Z0011 eligibility criteria. Axillary tumor burden is higher in these patients than in the ACOSOG Z0011 trial.

Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?

2017 ◽  
Vol 23 (5) ◽  
pp. 554-562 ◽  
Author(s):  
Olga Kantor ◽  
Catherine Pesce ◽  
Erik Liederbach ◽  
Chi-Hsiung Wang ◽  
David J. Winchester ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Acosog Z0011 ◽  
Z0011 Trial

Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial

2021 ◽  
Vol 27 (3) ◽  
pp. 216-221
Author(s):  
Joshua Tseng ◽  
Rodrigo F. Alban ◽  
Emily Siegel ◽  
Alice Chung ◽  
Armando E. Giuliano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Invasive Breast Cancer ◽  
Axillary Dissection ◽  
Sentinel Node Metastasis ◽  
Node Metastasis ◽  
Acosog Z0011 ◽  
Z0011 Trial

scholarly journals Eligibility for ACOSOG Z0011 Trial and Results on a Cohort of 3546 Breast Cancer Patients with Micro or Macro Metastases Sentinel Nodes

2020 ◽  
Vol 03 (01) ◽  
Author(s):  
Houvenaeghel G ◽  
Cohen M ◽  
Marc M ◽  
Barrou J ◽  
Lambaudie E ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Sentinel Nodes ◽  
Acosog Z0011 ◽  
Z0011 Trial
Sign in / Sign up

Export Citation Format

Share Document